Yash Patel

Yash Patel inquired about the current payer dynamics for PALSONIFY, specifically asking if there has been any significant pushback or new step-edit requirements from payers.

Answer

Isabel Kalofonos, Chief Commercial Officer, reported positive market access progress with no significant barriers to treatment. She noted that most coverage is based on PALSONIFY's label, prior authorizations are proceeding well, and medical exceptions are handled effectively. She also mentioned that 50% of claims were pre-reimbursed and 60% moved into Quick Start in Q4, with a commitment to transition Quick Start patients faster than the rare disease average.

Yash Patel, on behalf of Gavin Clark-Gartner, asked about the current payer dynamics for PALSONIFY, specifically if there's significant pushback or new step edits.

Answer

Chief Commercial Officer Isabel Kalofonos expressed satisfaction with market access progress, noting no significant barriers to treatment. She stated that most coverage is based on PALSONIFY's label, with prior authorizations and medical exceptions proceeding well. She also mentioned that 50% of claims were pre-reimbursed and 60% moved into QuickStart in Q4, with a commitment to faster QuickStart transitions.